{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:22:10Z","timestamp":1763018530819,"version":"build-2065373602"},"reference-count":21,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized for underlying diseases not related to COVID-19. We conducted a retrospective analysis regarding molnupiravir therapy in patients with SARS-CoV-2 infection admitted for underlying diseases not associated with COVID-19. Forty-four patients were included. The median age was 79 years (interquartile range [IQR]: 51\u201393 years), and most males were 57,4%. The median Charlson Comorbidity Index and 4C score were, respectively, 5 (IQR: 3\u201310) and 9.9 (IQR: 4\u201312). Moreover, 77.5% of the patients had at least two doses of the anti-SARS-CoV-2 vaccine, although 10.6% had not received any SARS-CoV-2 vaccine. Frequent comorbidities were cardiovascular diseases (68.1%), and diabetes (31.9%), and most admissions were for the acute chronic heart (20.4%) or liver (8.5%) failure. After molnupiravir started, 8 (18.1%) patients developed acute respiratory failure, and five (11.4%) patients died during hospitalisation. Moreover, molnupiravir treatment does not result in a statistically significant change in laboratory markers except for an increase in the monocyte count (p = 0.048, Z = 1.978). Molnupiravir treatment in our analysis was safe and well tolerated. In addition, no patients\u2019 characteristics were found significantly related to hospital mortality or an increase in oxygen support. The efficacy of the molecule remains controversial in large clinical studies, and further studies, including larger populations, are required to fill the gap in this issue.<\/jats:p>","DOI":"10.3390\/antibiotics11111541","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T05:04:34Z","timestamp":1667451874000},"page":"1541","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-9519","authenticated-orcid":false,"given":"Tommaso","family":"Lupia","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Corcione","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"},{"name":"School of Medicine, Tufts University, Boston, MA 02111, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0171-9274","authenticated-orcid":false,"given":"Nour","family":"Shbaklo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Boglione","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine (DiMET), University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Torresan","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-1075","authenticated-orcid":false,"given":"Simone Mornese","family":"Pinna","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rizzello","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Bosio","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Fornari","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Brusa","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Borr\u00e8","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Saint Andrea Hospital, 13100 Vercelli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-0130","authenticated-orcid":false,"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy"},{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s42269-022-00753-9","article-title":"Antiviral activity of molnupiravir against COVID-19: A schematic review of evidences","volume":"46","author":"Singla","year":"2022","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e02428-20","DOI":"10.1128\/AAC.02428-20","article-title":"Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.4269\/ajtmh.21-1339","article-title":"Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial","volume":"106","author":"Thorlund","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_6","first-page":"e32","article-title":"Molnupiravir for COVID-19 in Nonhospitalized Patients","volume":"386","author":"Thorlund","year":"2022","journal-title":"New Engl. J. Med."},{"key":"ref_7","unstructured":"(2022, April 01). EMA Issues Advice on Use of Lagevrio (Molnupiravir) for the Treatment of COVID-19. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-issues-advice-use-lagevrio-molnupiravir-treatment-covid-19."},{"key":"ref_8","unstructured":"(2022, April 01). Conditions of Use of Molnupiravir. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-conditions-use-conditions_en.pdf."},{"key":"ref_9","unstructured":"(2022, April 08). Leading Causes of Hospitalization in Italy in 2016. Available online: https:\/\/www.statista.com\/statistics\/935631\/number-of-hospital-admissions-by-cause-in-italy\/."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Vena, A., Traman, L., Bavastro, M., Limongelli, A., Dentone, C., Magn\u00e8, F., Giacobbe, D.R., Mikulska, M., Taramasso, L., and Di Biagio, A. (2022). Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression. Vaccines, 10.","DOI":"10.3390\/vaccines10071141"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"De Vito, A., Colpani, A., Bitti, A., Zauli, B., Meloni, M.C., Fois, M., Denti, L., Bacciu, S., Marcia, C., and Maida, I. (J. Med. Virol., 2022). Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: A real-life experience, J. Med. Virol., Epub ahead of print.","DOI":"10.1002\/jmv.28011"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101205","DOI":"10.1016\/j.arr.2020.101205","article-title":"Aging in COVID-19: Vulnerability, immunity and intervention","volume":"65","author":"Chen","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"De Rosa, F., Palazzo, A., Rosso, T., Shbaklo, N., Mussa, M., Boglione, L., Borgogno, E., Rossati, A., Pinna, S.M., and Scabini, S. (2021). Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091951"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.cmet.2020.07.007","article-title":"Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1\u03b1\/Glycolysis-Dependent Axis","volume":"32","author":"Codo","year":"2020","journal-title":"Cell Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"720109","DOI":"10.3389\/fimmu.2021.720109","article-title":"Monocytes and Macrophages in COVID-19","volume":"12","author":"Knoll","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Arribas, J.R., Bhagani, S., Lobo, S.M., Khaertynova, I., Mateu, L., Fishchuk, R., Park, W.Y., Hussein, K., Kim, S.W., and Ghosn, J. (2022). Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with COVID-19. NEJM Evid., 1.","DOI":"10.1056\/EVIDoa2100044"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wong, C.K.H., Au, I.C.H., Lau, K.T.K., Lau, E.H.Y., Cowling, B.J., and Leung, G.M. (Lancet Infect. Dis., 2022). Real-world effectiveness of early molnupiravir or nirmatrelvir\u2013ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong\u2019s omicron BA.2 wave: A retrospective cohort study, Lancet Infect. Dis., Epub ahead of print.","DOI":"10.1016\/S1473-3099(22)00507-2"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yip, T.C.F., Lui, G.C.Y., Lai, M.S.M., Wong, V.W.S., Tse, Y.K., Ma, B.H.M., Hui, E., Leung, M.K., Chan, H.L.Y., and Hui, D.S.C. (Clin. Infect. Dis., 2022). Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients, Clin. Infect. Dis., Epub ahead of print.","DOI":"10.2139\/ssrn.4112160"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Khoo, S.H., FitzGerald, R., Saunders, G., Middleton, C., Ahmad, S., Edwards, C.J., Hadjiyiannakis, D., Walker, L., Lyon, R., and Shaw, V. (Lancet Infect. Dis., 2022). Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): A randomised, placebo-controlled, double-blind, phase 2 trial, Lancet Infect. Dis., Advance online publication.","DOI":"10.1016\/S1473-3099(22)00644-2"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Boglione, L., Corcione, S., Shbaklo, N., Lupia, T., Scabini, S., Pinna, S.M., Borr\u00e8, S., and De Rosa, F.G. (Infect. Dis. Health, 2022). Predictors of mortality in patients with COVID-19 infection in different health-care settings: A retrospective analysis from a CORACLE study group, Infect. Dis. Health, Epub ahead of print.","DOI":"10.1016\/j.idh.2022.05.006"},{"key":"ref_21","first-page":"80","article-title":"Liver involvement and mortality in COVID-19: A retrospective analysis from the CORACLE study group","volume":"30","author":"Boglione","year":"2022","journal-title":"Infez. Med."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/11\/1541\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:09:50Z","timestamp":1760144990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/11\/1541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["antibiotics11111541"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11111541","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}